Nathan Jeppesen, DPM
Foot & Ankle Surgery · Mesa, AZNPI 1306088307
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,500 of the $9,774 with a category attached, or 76.7%. Medartis Inc. accounts for 85.5% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $8,638 and has fallen 99.1% since, to $74 in 2025.
Across 75 payments — averaging $130.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medartis Inc.$8K
- Stryker$305
- Smith+Nephew$228
- Dynasplint Systems Inc.$125
- AbbVie$90
- Amgen$81
- plus $585 from 18 others
What the payments were for
- Speaking & faculty fees$7,50077%
- Travel & lodging$6196%
- Food & beverage$1,64417%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medartis Inc. | 5 | $8,360 |
| Stryker(2 entities) | 8 | $305 |
| Smith+Nephew | 12 | $228 |
| Dynasplint Systems Inc. | 3 | $125 |
| AbbVie | 4 | $90 |
| Amgen | 5 | $81 |
| Orthofix Medical, Inc. | 12 | $72 |
| Bioventus LLC | 4 | $66 |
| Pacira Pharmaceuticals Incorporated | 1 | $55 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $49 |
| Amniox Medical, Inc. | 2 | $45 |
| Organogenesis Inc. | 2 | $40 |
| Impactortho, Inc. | 2 | $39 |
| Triad Life Sciences Inc. | 1 | $32 |
| GRT US Holding, Inc. | 1 | $29 |
| Acell, Inc. | 1 | $25 |
| Medtronic | 1 | $22 |
| Medela LLC | 1 | $19 |
| Forthright Medical - AZ, LLC | 2 | $18 |
| Misonix Inc | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Osteomed LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,774 in reported general payments places this provider in the 75th percentile of 291 foot & ankle surgery providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 56 | $1,603 |
| Pregabalin | 33 | $614 |
| Gabapentin | 57 | $579 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 24 | $543 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 14 | $380 |
| Celecoxib | 40 | $354 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $229 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $119 |
| Methylprednisolone | 15 | $107 |
| SsdSilver Sulfadiazine | 14 | $88 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $60 |
| Tramadol Hcl | 15 | $54 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Mesa
- Scott MalingMesa$382K
- Jordan SistoMesa$54K
- Clay ShumwayMesa$32K
- Justin SinghMesa$30K
- Chase MoffatMesa$24K
- Jason HarrillMesa$16K
- Christopher SuykerbuykMesa$13K
- Ryan ScottPhoenix$1.1M
- Jeffrey McAlisterScottsdale$578K
- Jeffrey HolmesPhoenix$509K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.